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Abstract
Background: The simplicity and potential of minimal invasive testing using serum from patients make auto-
antibody based biomarkers a very promising tool for use in diagnostics of cancer and auto-immune disease.
Although several methods exist for elucidating candidate-protein markers, immobilizing these onto membranes
and generating so called macroarrays is of limited use for marker validation. Especially when several hundred
samples have to be analysed, microarrays could serve as a good alternative since processing macro membranes is
cumbersome and reproducibility of results is moderate.
Methods: Candidate markers identified by SEREX (serological identification of antigens by recombinant expression
cloning) screenings of brain and lung tumour were used for macroarray and microarray production. For microarray
production recombinant proteins were expressed in E. coli by autoinduction and purified His-tag (histidine-tagged)
proteins were then used for the production of protein microarrays. Protein arrays were hybridized with the serum
samples from brain and lung tumour patients.
Result: Methods for the generation of microarrays were successfully established when using antigens derived from
membrane-based selection. Signal patterns obtained by microarrays analysis of brain and lung tumour patients’
sera were highly reproducible (R = 0.92-0.96). This provides the technical foundation for diagnostic applications on
the basis of auto-antibody patterns. In this limited test set, the assay provided high reproducibility and a broad
dynamic range to classify all brain and lung samples correctly.
Conclusion: Protein microarray is an efficient means for auto-antibody-based detection when using SEREX-derived
clones expressing antigenic proteins. Protein microarrays are preferred to macroarrays due to the easier handling
and the high reproducibility of auto-antibody testing. Especially when using only a few microliters of patient
samples protein microarrays are ideally suited for validation of auto-antibody signatures for diagnostic purposes.
Background
The idea of early diagnosis of the onset of a disease via
biomarkers has inspired several molecular biological
approaches. In the past decade, since the unravelling of
the human genome to a large extent, genomics technol-
ogies have been used to identify disease biomarkers. For
cancerous diseases recently the most promising results
were obtained by gene expression profiling. Excellent
results have been achieved with these techniques in
terms of improved patient stratification and increased
potential of a clearer prognosis by a more detailed initial
d i a g n o s i s .H o w e v e r ,t h et r u ec h a l l e n g ei st od e v e l o p
techniques which are suitable for early diagnosis and
prophylactic screening. These techniques should be
minimally invasive, cost effective and ideally they indi-
cate several diseases of the screened patient [1].
Proteomics techniques have shifted biomarker identifi-
cation and validation research to the level of the main
actual biological agents of health and disease, the proteins.
Despite recent improvements in separation techniques
based on HPLC (High-performance liquid chromatogra-
phy) separation, mass spectrometry and 2D electrophor-
esis, so far the novel biomarker candidates and biomarker
signatures which are ready for the use in clinical settings
have proven to require detection steps similarly complex
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use in the screening of large populations [1].
Ideally the proteomics based techniques result in the
identification of marker molecules that can be targeted
in specialized assays relying on antibodies or aptamers
[2-4]. The development of specific capturing agents for
the candidate markers requires a costly production pro-
cess and thorough validation. This ensures high avidity
for the target while minimizing the risk of unspecific
binding.
In the auto-antibody approach these issues are
sophisticatedly avoided. The need to identify aberrant
nucleic acid sequences, disease related biochemical
compounds, disease affected cells or their debris is
r e d u c e db ym a k i n gu s eo fah i g h l ys e n s i t i v ed e t e c t i o n
system closest to the patient, the human immune sys-
tem. Mutated, modified and aberrantly expressed pro-
teins evoke an immunological response leading to the
production of auto-antibodies [5,6]. The auto-antibody
based biomarkers could be used as serological tool for
the early diagnosis and prognosis of cancer as auto-
antibodies are specific to each kind of cancer [5,7,8].
Most of the auto-antibodies are immunological finger
prints of pathological processes which are involved in
the development of autoimmunity [5]. Such a molecu-
lar finger print of auto-antibodies which is produced
against certain disease states can be called auto-
antibody signature [7]. Assays for the detection of
auto-antibodies at present are mainly ELISA (enzyme
linked immunosorbent assay) and fluorescence immu-
noassays. However, protein microarrays have great
potential to characterize auto-antibodies [9].
Strategies like the SEREX have been developed for the
serological definition of immunogenic tumour antigens
[10-13]. A similar approach has been used successfully
for the identification of tumour endothelium associated
antigen genes from human liver cancer vascular endothe-
lial cells by generating a cDNA expression library. For
the identification of auto-antibodies against pancreatic
ductal adenocarcinoma-associated antigens which could
be useful for early cancer diagnosis and therapy, a pro-
teomics approach was followed up [14,15]. Proteins from
pancreatic ductal adenocarcinoma cell lines were sepa-
rated by 2D electrophoresis, and the serum IgG (immu-
noglobulin G) reactivity was tested by Western blot
analysis. Spots specifically reacting with auto-antibodies
from the sera of pancreatic ductal adenocarcinoma
patients, which were analyzed by mass spectrometry, cor-
responded to metabolic enzymes or cytoskeletal proteins
which proved to be specific targets of the humoral
response to pancreatic ductal adenocarcinoma.
Over recent years most approaches have used so called
macroarrays for autoantigen-profiling. These macroar-
rays are generated by spotting cDNA expression clones
on membranes. Expression clones are grown on these
membranes and recombinant proteins over-expressed
upon induction are directly immobilized on the reactive
membrane surfaces. Because entire colonies are lysed
directly on the membranes and proteins of interest are
immobilized in the background of the proteins of the
expression-host bacteria, the targeted proteins are acces-
sible for detection only after removal of the reactive anti-
E. coli-Ig (immunoglobulin) from the analyte. This can
be achieved either by masking of the anti-E. coli anti-
bodies in human sera by addition of saturating concen-
trations of E. coli crude protein extracts and by blocking
unwanted reactivity against E. coli by repeated incubation
of membranes with the human serum. In this latter
approach reactive Ig’s from sera are captured by the
macroarrays, sera are collected upon this primary incuba-
tion and after washing/stripping the membranes the sera
are applied again onto the membranes obtaining then the
signal from the Ig’ss p e c i f i cf o rt h er e a c t i v eo v e r -
expressed antigens. Handling membranes and processing
sera is cumbersome, and sensitivity and reproducibility of
these macroarrays are limiting. Signals derived from
membranes are not dynamic. In analogy to western blot-
ting different strategies exist to enhance sensitivities and
to extend the dynamic range of membrane-based mea-
sures, but are rather limiting compared to the 16 bit
(0-2
16) dynamic range of standard microarrays.
In this study we optimized methods for generation of
protein microarrays and provided an optimized proto-
col for generation of biomarker profiles with high
reproducibility using 10 μL amounts of patient serum
samples. The provided data do also confirm that clones
derived from SEREX membrane screens can be suc-
cessfully transferred onto microarray slides retaining
reactivity and gaining dynamic signal measures suitable
for class-comparison to elucidate and validate protein-
biomarkers.
Methods
Candidate marker screening
T h ec a n d i d a t em a r k e r sw e r ei d e n t i f i e db yp r e v i o u s
SEREX screenings of brain and lung cancer, and
screening macroarrays of a fetal brain cDNA expres-
sion library. Potential tumour associated antigens
d e r i v e df r o mS E R E Xs c r e e n sw e r ei s o l a t e da n ds u b
cloned in the expression vector pQE30NST for pro-
duction of His-tag (histidine-tagged) fusion proteins
[16-20]. Marker candidate screening involved testing of
serum from lung tumour patients and from brain
tumour patients as well as control sera under the
patients’ informed consent. The local ethics committee
(Ärztekammer des Saarlandes, Kenn-Nr. 213/08)
approved the study and the research was carried out in
compliance with the Helsinki Declaration.
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E. coli culturing and induction was performed in 96well
format with slight modifications [20]. Recombinant pro-
tein expression was induced either by IPTG (Isopropyl
b-D-1-thiogalactopyranoside) or by cultivation of bacter-
ial clones in autoinduction medium (1 mL) [21]. Upon
cultivation His-tagged recombinant proteins were puri-
fied using Ni-NTA (nickel immobilized onto agarose
resin via nitrilo triacetic acid) agarose and chosen elu-
tion conditions were adopted warranting protein-
binding onto ARChip Epoxy coated slides [22]. Elution
of His-tag protein was done using 500 mM imidazole.
Purified proteins were electrophoresed and analyzed
using standard procedures. Protein eluates from Ni-
metal-chelate purification were controlled for specificity
via a His-Tag antibody ELISA. Protein antigens were
printed in triplicates on ARChip Epoxy glass slides.
Crude clarified protein extracts of the E. coli host was
used for positive control spots, plain buffer spots were
used as negative controls. The detailed protocols are
available from the supplement (see additional file 1:
detailed information on methodology).
Assay protocols
Reactive groups on the slide surface were blocked for
2 h in PBST (Phosphate buffered saline with 0.1%
Tween 20) blocking buffer with 5% non-fat milk pow-
der. Slides were washed 2 times 5 min in PBST wash
buffer, rinsed with distilled water and blown dry with
filtered air. Arrays were incubated for 1 h with patients’
sera and control sera diluted 1:10 in blocking buffer.
U p o nw a s h i n gt w i c ef o r5m i ni nw a s hb u f f e r ,s l i d e s
were rinsed with distilled water and blown dry with fil-
tered air. Arrays were incubated for 1 h with goat anti
human IgG detection antibody fluorescently labelled
with Alexa647 dye (Invitrogen, Lofer, Austria), diluted
1:500 in blocking buffer. Following the final washing
steps of twice 5 min washing in wash buffer, arrays were
rinsed with distilled water and dry-blown. Array images
were captured using an Axon Genepix 4000A microar-
ray scanner (Molecular Devices, Union City, CA).
Data analysis
Fluorescence intensities - medians after subtraction of
the local background - were calculated from the scanned
array images with the Genepix software (Molecular
Devices, Union City, CA). Statistical data analysis was
performed using R version 2.6.2, BRB-ArrayTools Ver-
sion: 3.6.0 - Stable Release, limma software package and
nearest shrunken centroid algorithm [19,23,24]. The
nearest shrunken centroid algorithm is used to find out
the clusters in the samples using hierarchical clustering
methods on expression arrays [25].
Results
Methods optimization
The bacterial wet biomass (30 mg/mL culture) obtained by
autoinduction was twice when compared to that of
obtained from IPTG cultures. Using Ni-NTA-metal che-
late purification the amount of purified protein from 1 mL
of bacterial culture (autoinduced) was 7-70 ng at an aver-
age concentration of about 0.2-0.25 mg in 75 μLo fe l u -
tion-buffer. Protein yields were similar with both methods
which points towards similar effectiveness in protein
expression. The expression rate of recombinant proteins
was 40% for both IPTG and autoinduction as determined
by Penta-His antibody ELISA. Although there were some
minor differences between different batches of 1 mL bac-
terial cultures grown in 96well plates and distinct runs of
protein-purification it becomes clear that both induction
methods of recombinant protein expression were equally
successful (see additional file 1: detailed information on
methodology). When several repeated experiments did not
show a great difference between both induction strategies,
we continued with the autoinduction method because of
easier technical handling.
It was found out that the amount of His-tag protein
yielded upon elution using 250 and 500 mM imidazole
to be more or less the same. Eventually, we used 500
mM imidazole for elution of all proteins which were
used for microarray printing.
Optimizations for processing the protein-arrays cov-
ered the 1) blocking-reagent, 2) serum-incubation time,
and 3) detection of serum-auto-antibodies using anti-
humanIg-Alexa647 conjugate. Addition of 5% non-
fat-dry milk into PBST was efficient when blocking
slides for 30 min at room temperature. Prolonged block-
ing did not significantly increase signal to noise ratios.
Although bovine serum albumin has been described for
blocking, milk powder is an efficient and an inexpensive
alternative. Omission of the milk powder, however led
to strong unspecific binding of serum-proteins to the
microarray and thereby to high background signals.
We tested serum-incubation time with respect to signal
intensities of microarray spots. Using a 1:10 dilution of
sera from healthy controls in PBS (Phosphate buffered
saline) signal intensities reached a plateau after 2 h incu-
bation at room temperature. Signal intensities upon 4 h
incubation were comparable to intensities after 2 h incu-
bation. Therefore, a 2 h serum-incubation step was used
for all further tests and found to give sufficiently high sig-
nals to identify clear and distinct auto-antibody patterns
from controls as well as from patient’ss a m p l e s .( S e e
additional file 2: figure displaying the detailed layout of
the antigen-microarray). Negative control experiments
conducted without serum excluded unspecific binding of
the anti-human Ig-Alexa647 detection antibody and
Stempfer et al. BMC Cancer 2010, 10:627
http://www.biomedcentral.com/1471-2407/10/627
Page 3 of 8indicate that the detection step is specific to human auto-
antibodies. Thus, spot signals are derived from specific
serum antibody-binding with the antigens presented on
the chip. No direct correlation of the amounts of spotted
protein with the yielded signal strengths could be
detected. Hence, the yielded signals are due to the pre-
sence of antibodies specific to the target proteins and not
to unspecific binding which would clearly correlate with
protein mass. Positive control spots of E. coli crude pro-
tein extracts showed high signals indicating the presence
of high levels of antibodies against E. coli proteins in the
sera of all donors and patients, whereas buffer spots serve
as controls were clearly negative. Thus, false positive-sig-
nals derived from carry-over of reactive proteins from
printing spots with the same set of pins during microar-
ray fabrication can be excluded. (See additional file 2:
figure displaying the detailed layout of the antigen-micro-
array). Here, we want to mention that recombinant pro-
teins derived from single step Ni-His(6)-affinity protein
purification are not pure and will contain several percen-
tages of E. coli proteins, which could be problematic
when covering specific signals. This, however, might be
especially true for primary-screens to identify specific
antigens from clone libraries. In our setting all clones
used for antigen-purification and microarray fabrication
were selected via several pre-screens within the SEREX
procedure (see methods and additional file 1: detailed
information on methodology). Reactivity of the spotted
proteins was not covered by serum-reactivity against
remaining E. coli proteins, therefore, the microarray
enabled a specific and clear differentiation between sera
derived from lung cancer and brain cancer patients.
Serum samples have been initially tested during the
SEREX-membrane screen. Some subsets of clones which
have been tested positive with several patient sera were
used for evaluation of protein microarrays. On the chip,
binding of auto-antibodies to the candidate marker pro-
teins was observed as demonstrated in the initial SEREX
screens (Figure 1). Binding events detected in addition
to the marker candidates that were expected from
macro-membrane screens (in analogy to SEREX screens)
indicate greater detection limit/signal intensity of the
microarray when compared to the membrane method.
This might be due to the smaller reaction surfaces and
better distribution of the serum-sample over the array
(Figure 1). Moreover, this greater detection limit/signal
intensity is achieved with a few microliters of analyte
i.e., 1:10 diluted sera (about 75 μL is sufficient for wet-
ting the entire area of a standard slide).
Performance of microarray based serum-auto-antibody
testing
Detection using anti-human Ig-Alexa647 conjugate upon
application of patients’ sera to the blocked arrays yielded
clearly visible binding patterns that already at an optical
level displayed almost identical patterns. Also the control
sera yielded specific patterns, yet different to the ones of
patient’s sera. Pair-wise correlation plots of repetitive
serum-testing on different slides confirmed the high
reproducibility of the signal patterns and results in corre-
lation coefficients ranging from 0.92 to 0.96 of (Figure 1).
Statistical data analyses of brain and lung cancer serum-
microarray data was performed in analogy to gene-
expression microarray data analysis using the limma
software package. Figure 2 shows the normalised signal
intensities of the three most differentially reactive clones
between brain and lung. It shows that across replicate
measurements the assay is capable of distinguishing these
two biological classes. For these genes, both technical
variances and within-group variances are small, com-
pared to the between-group variances. Therefore it is not
surprising, that when attempting to build a classification
rule using the nearest shrunken centroid algorithm on
replicate-1 and testing this rule on replicate-2, all sam-
ples are classified correctly. In the reverse case (building
the rule on replicate-2 and testing it on replicate-1), one
sample is misclassified. The good separation between the
two classes is also visualised in Figure 3.
Discussion
Auto-antibodies are very potent biomarkers which
would be useful for minimal invasive testing for early
diagnosis of autoimmune and cancerous disease. Beside
SEREX-based screening using immobilized expression
clones on membranes, macroarrays with several thou-
sand expression-clones derived from human cDNA
libraries are suitable platforms for screening for deter-
mining reactive clones over-expressing proteins which
are biomarker-candidates [19]. However, the mem-
brane based clones are not a versatile tool for valida-
tion of those candidate makers. Drawbacks of
membrane based screening are low reproducibility, low
dynamic range of signal intensities, and difficulties in
handling membranes. In addition to these technically
problems, several hundred microliters of patient serum
for processing the membranes or macroarrays are
required. Because sample size of clinically well docu-
mented samples is always limited, miniaturization of
assays using microarrays w o u l db eag r e a to p t i o nt o
save samples (about 75 μL of sample is sufficient to
cover an entire 1 × 2 inch standard slide). As known
from the performance of DNA-microarrays, obtaining
high reproducibility, high dynamic range of intensity-
measures (usually in the range of 4-6 orders of magni-
tudes; derived form 16 or 20 bit microarray scanners)
and easy handling microarrays, protein microarrays
would be a potential alternative for validation of dis-
ease specific serum-auto-antibody profiles.
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evaluate their performance with respect to technical
aspects like reproducibility and suitability using patient
serum samples already used for candidate biomarker
screening. Therefore we set up techniques and opti-
mized with respect to 1) recombinant protein expression
from candidate clones, 2) protein-purification in a 96
well standard plate format and microarray printing, and
3) finding best conditions of serum-testing on antigen-
microarrays (see methods and additional file 1: a
detailed information on methodology). We have found
during optimization (data not shown) of protein micro-
array production that proteins concentrations of up to
0.5 mg/mL are well suited for spotting using a contact
Figure 1 Pair wise correlation of repeated protein microarray analyses. Pair wise correlation of repeated analyses of serum samples. Log2
transformed unnormalised intensities, with a threshold set to 512 intensity-units (derived from Genepix .gpr files) were used for analyses.
Correlation coefficients are given in the paired scatterplots and were above 0.92 upon repetitive analyses. The “filled triangles” represent reactive
clones from each individual serum found within membrane-based macroarray testing. Data from repetitive analyses (replicate-1 on x-axes;
replicate-2 on y-axes) microarray analyses using serum from brain (left) and lung (right) tumour patients (identifiers of different patient sera on
top of each scatter plot) are plotted.
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arrays perform well (with respect to signal intensities
and spot morphology) and at that concentration clog-
ging of microarrayer-pins is also avoided.
Upon protein-purification using His-tag/Ni-affinity we
measured protein-concentrations and determined speci-
fic recombinant proteins using a His-tag-ELISA.
Although we have not compared microarrays generated
from different batches of protein-purification the ratio
of His-tag-ELISA signals and protein-concentration
would be a practicable measure of “purity” which should
be taken into consideration when using different pro-
tein-batches for microarray generation. Although the
“different slide batch effect” is known also from DNA-
chips, this would be clearly more critical using proteins
derived from different batches of clone-cultivation,
expression and purification. Therefore, while using (pro-
tein) microarrays for screening purposes defining bio-
markers would be done best when using the same batch
of microarrays avoiding these effects. When not avoid-
able that must be considered by proper experimental
planning. We found out that the membrane-blot derived
classifiers (which enabled distinction of brain and lung
tumour serum antibody profiles) did perform well also
on the microarray-derived data set, confirming the relia-
bility of the reactive markers. This is true even when
data were derived from two entirely distinct methodolo-
gies. Membrane blots are generated by fixation of pro-
teins upon growing E. coli clones on membranes and
microarrays are spotted using proteins from distinct
1 ml culturing of clones. Optimized conditions for
obtaining maximum signal intensities on microarrays
were achieved with 1:10 serum dilutions after 2 h incu-
bation at room temperature. Thus arrays covering an
entire standard slide can be processed with only 10 μL
of serum. This would enable paralleled detection of
about 20000 different spots, a spot density usually
achieved with standard microarray printing techniques.
We could also show the high reproducibility of protein
microarray-data. Correlation coefficients of repeated
analyses using patient sera were in the range of 0.919-
0.971 (median 0.957). While the differentially reactive
clones identified in this study need more independent
testing to prove their usefulness as clinical markers, we
have shown that the assay is capable of detecting differ-
ences between biological groups which are stable and
Figure 2 Replicate measurements of the top three differentially reactive clones. Performance of the top three differentially reactive clones
(B5, E7 and D11 with p-values less than 0.002, 0.01, 0.05, respectively) in replicate experiments. The normalized signal intensity values of these
reactive clones across the replicate measurements (replicate-1 and -2) distinguishes between brain (n = 5) and lung (n = 5) cancer serum
samples.
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ison and class prediction. Thus, this kind of microarrays
has several advantages over macroarrays and microarray
based testing of patient samples is the method of choice
for highly paralleled auto-antibody testing. Especially
when many different samples have to be processed for
validation of biomarker candidates, handling many
microarrays is much easier and also for screening
approaches microarrays are best suited and will replace
membrane-based macroarray screens. Biostatistical ana-
lysis of high-dimensional data derived from microarray-
feature intensities is also well established and can be
used in the analysis of auto-antibody data.
Conclusion
In conclusion, herewith, we successfully demonstrate the
feasibility for auto-antibody identification technology by
means of recombinant protein expression and arraying the
proteins on microarray solid supports. Because panels of
auto-antigens rather than individual antigens enhance the
likelihood of detecting cancer antigens with diagnostic
potential [26-28], highly paralleled detection of auto-
antibody signatures yielded from this platform will be aiding
disease diagnosis and improve patient stratification [19,29].
Additional material
Additional file 1: Supplemental information. Detailed information on
methodology
Additional file 2: Microarray layout. Figure displaying the detailed
layout of the antigen-microarray
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